Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tenapanor Hydrochloride
Therapeutic Area : Nephrology
Study Phase : Approved FDF
Sponsor : Ardelyx
Deal Size : Inapplicable
Deal Type : Inapplicable
Fosun Pharma Received NMPA Approval for Wan Ti Le (Tenapanor Hydrochloride Tablets)
Details : Wan Ti Le (tenapanor HCl) is a sodium/hydrogen exchanger 3 (NHE3) inhibitor indicated for treatment of chronic kidney disease.
Product Name : Wan Ti Le
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 26, 2025
Lead Product(s) : Tenapanor Hydrochloride
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Sponsor : Ardelyx
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Artemether,Amodiaquine,Lumefantrine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : GHIT Fund
Deal Size : $3.3 million
Deal Type : Financing
Details : The financing will be used for a clinical phase III trial for a fixed-dose combination of artemether-lumefantrine-amodiaquine drug (three existing antimalarial drugs already developed, marketed and sold) against malaria.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 13, 2023
Lead Product(s) : Artemether,Amodiaquine,Lumefantrine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : GHIT Fund
Deal Size : $3.3 million
Deal Type : Financing
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Artesun (artesunate) is rapidly metabolized into an active metabolite DHA which contains an endoperoxide bridge that is activated by heme iron leading to oxidative stress, inhibition of protein and nucleic acid synthesis, which decreases parasite growth ...
Product Name : Artesun
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 26, 2023
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palonosetron
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Helsinn Advanced Synthesis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Helsinn will grant Fosun an exclusive license to distribute, promote and sell the following products in the aforesaid territory: Aloxi (Palonosetron hydrochloride), Akynzeo (Netupitant and Palonosetron hydrochloride) and NEPA (Fosnetupitant and Palonoset...
Product Name : Aloxi
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 10, 2021
Lead Product(s) : Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Helsinn Advanced Synthesis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Tozinameran
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : BioNTech
Deal Size : $100.0 million
Deal Type : Collaboration
BioNTech, Fosun Pharma Entering Into Term Sheet in Relation to Formation of a Joint Venture
Details : A unit of Shanghai Fosun Pharmaceutical has agreed to form a US$200 million joint venture with German partner BioNTech to build a plant in China capable of supplying up to 1 billion doses of coronavirus vaccine (BNT162b2) a year.
Product Name : BNT162b2
Product Type : Vaccine
Upfront Cash : Undisclosed
August 05, 2021
Lead Product(s) : Tozinameran
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : BioNTech
Deal Size : $100.0 million
Deal Type : Collaboration
Lead Product(s) : Tozinameran
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Fosun Submits Trial Data of Foreign Covid-19 Vaccine for State Review
Details : Fosun Pharm has submitted the clinical trial data of a COVID-19 mRNA vaccine (BNT162b2) co-developed with German BioNTech and relevant materials to China's state regulator for rolling review.
Product Name : BNT162b2
Product Type : Vaccine
Upfront Cash : Inapplicable
April 18, 2021
Lead Product(s) : Tozinameran
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FCN-338
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Eli Lilly
Deal Size : $440.0 million
Deal Type : Licensing Agreement
Details : Lilly gains exclusive rights to develop and sell FCN-338 in all countries and regions except for Mainland China, Macao, and Hong Kong. Fochon reserves all right to research, develop, register, manufacture, and market FCN-338 in Mainland China, Macao, and...
Product Name : FCN-338
Product Type : Other Small Molecule
Upfront Cash : $40.0 million
October 30, 2020
Lead Product(s) : FCN-338
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Eli Lilly
Deal Size : $440.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Leflunomide
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Wanbang’s Leflunomide Tablets Get FDA Nod, Set to Enter U.S. Market
Details : Leflunomide is an immunomodulatory drug that inhibits the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH), in patients with rheumatoid arthritis.
Product Name : Leflunomide-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 12, 2020
Lead Product(s) : Leflunomide
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BNT162
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : BioNTech
Deal Size : Inapplicable
Deal Type : Inapplicable
China's Fosun to End BioNTech's COVID-19 Vaccine Trial, Seek Approval for Another
Details : Fosun will focus instead on seeking Chinese approval for BioNTech’s other experimental vaccine which is in final-stage human trials in the United States, Fosun’s Chief Medical Officer Hui Aimin told Reuters in an interview.
Product Name : BNT162
Product Type : Vaccine
Upfront Cash : Inapplicable
April 11, 2020
Lead Product(s) : BNT162
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : BioNTech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pretomanid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : TB Alliance
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The partnership with Hongqi is part of TB Alliance’s global commercialization strategy for pretomanid as part of the BPaL regimen.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
January 16, 2020
Lead Product(s) : Pretomanid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : TB Alliance
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
